Recursion Pharmaceuticals Inc vs iShares TIPS Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while iShares TIPS Bond ETF trades at $107.93. Which is the better fit depends on your goals.
| RXRX | TIP | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $112.20 |
52-Week Low | $2.84 | $107.91 |
Enterprise Value | $946.50M | — |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
TIP trades at $108.05, down 0.2% today, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The stock lacks disclosed valuation metrics like P/E and P/S, and recent news highlights bond market volatility and Federal Reserve uncertainty influencing investor sentiment. Dividend payments are scheduled for 2026, providing income visibility.
Outlook is cautious due to bearish technical signals and macroeconomic risks from potential Fed rate hikes. Investment opportunities include dividend income, but risks involve market volatility and lack of current fundamental data. Investors should await earnings reports for clarity on financial health.
Trailing returns across standard periods
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →